Based on these evidences, we conducted a phase II trial to investigate the efficacy of pamiparib, with 16-fold higher PARP1 trapping capability compared to olaparib demonstrated in an in vivo HR-deficient xenograft model [25], in consolidation therapy for LS-SCLC. This evidence concerns the gene PARP1 and small cell lung carcinoma.